William Sutherland

Gene Mannheimer

Anthony Vendetti

Bradford Seagraves

Carl Byrnes

Joshua Cohen

Thomas McGovern

Tom McGovern

- Nutex Health Inc. is facing a **class-action lawsuit** alleging a deceptive billing strategy and financial misrepresentation, with a class period from **August 8, 2024, to August 14, 2025**.  **[1479681_20251021SF02627:0]** 
- The lawsuit claims Nutex collaborated with third-party billing firm HaloMD to submit ineligible insurance claims, artificially boosting financial results through the insurance arbitration process.  **[1479681_20251021SF02627:0]** 
- Following a short-seller report on **July 22, 2025**, Nutex shares dropped over **10%**, and further plunged **16.39%** on **August 15, 2025**, after the company delayed its Form 10-Q submission.  **[1479681_20251021SF02627:0]** 
- On **August 21, 2025**, Nutex disclosed that its Audit Committee determined certain prior financial statements required **restatement** due to incorrect classification of hospital development obligations and misclassification of stock-based compensation.  **[1479681_20251021SF02627:0]**  The lead plaintiff deadline for the class-action lawsuit is **October 21, 2025**.  **[1479681_20251021SF02627:0]**

Nutex Health Faces Class-Action Lawsuit and Financial Restatement

- Nutex Health reported **preliminary estimated patient volume** of **46,293** for Q3 2025, an **11.1% increase** year-over-year, and **estimated cash collections** of **$235,003 thousand**, a **258.8% increase** year-over-year.  **[1479681_0001479681-25-000085_a20251020-xfinmetricsxex991.htm:0]** 
- The company's Audit Committee determined that investors should **no longer rely** on previously issued unaudited condensed consolidated financial statements for Q1 2025 and audited consolidated financial statements for FY 2024 due to **errors in accounting treatment** of non-cash obligations related to earn-out arrangements.  **[1479681_0001479681-25-000085_a20251020-xfinmetricsxex991.htm:1]** 
- Nutex Health received a **Nasdaq non-compliance notice** for failing to timely file its Q2 2025 Form 10-Q.  **[1479681_0001479681-25-000085_a20251020-xfinmetricsxex991.htm:1]** **[1479681_0001479681-25-000085_nutx-20251020.htm:2]**  Nasdaq granted the company's request for an extension until **December 12, 2025**, to file the delinquent Q2 2025 Form 10-Q, and the Q3 2025 Form 10-Q is also anticipated to be filed later than its due date.  **[1479681_0001479681-25-000085_a20251020-xfinmetricsxex991.htm:1]** **[1479681_0001479681-25-000085_nutx-20251020.htm:2]**

Nutex Health Provides Q3 2025 Update and Addresses Financial Restatement and Nasdaq Compliance

- Nutex Health reported **preliminary Q3 2025 estimated patient volume of 46,293**, an **11.1% year-over-year increase**, and **estimated cash collections of $235,003 thousand**, a **258.8% year-over-year increase**.  **[1479681_20251020LA01610:0]** 
- The company determined that investors should **no longer rely** on previously issued financial statements for Q1 2025 and FY 2024 due to identified **accounting errors** related to earn-out arrangements.  **[1479681_20251020LA01610:0]** 
- This has led to a **delay in filing** its Q2 2025 Form 10-Q and a **Nasdaq non-compliance notice**.  **[1479681_20251020LA01610:0]** 
- Nutex Health has received an exception from Nasdaq, with a deadline of **December 12, 2025**, to file its delinquent Q2 2025 and Q3 2025 Form 10-Qs.  **[1479681_20251020LA01610:1]**

Nutex Health Provides Q3 2025 Preliminary Metrics and Corporate Update

- Pomerantz LLP has filed a class action lawsuit against Nutex Health Inc. and certain officers for alleged violations of federal securities laws during the period of **August 8, 2024, to August 14, 2025**.  **[1479681_20251018DC99977:0]** 
- The lawsuit alleges that Nutex made false and misleading statements, including that its revenues from the IDR process with HaloMD were unsustainable due to a fraudulent scheme and that the company overstated its ability to remediate material weaknesses in internal controls.  **[1479681_20251018DC99977:2]** 
- Following a Blue Orca Capital report on **July 22, 2025**, alleging fraud, Nutex's stock price fell **10.05%**.  **[1479681_20251018DC99977:2]** 
- Nutex subsequently announced a delay in its Q2 2025 10-Q filing and later disclosed that its Audit Committee concluded certain financial statements should be **restated** due to misclassification of non-cash obligations.  **[1479681_20251018DC99977:2]** **[1479681_20251018DC99977:3]** 
- On **August 21, 2025**, Nutex filed a Form 8-K including a **Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard**.  **[1479681_20251018DC99977:3]**

Nutex Health Faces Class Action Lawsuit and Financial Restatement

- Nutex Health Inc. (NUTX) is facing a class-action lawsuit alleging a **deceptive billing strategy** with third-party firm HaloMD, involving the submission of ineligible insurance claims to artificially boost financial results.  **[1479681_d56ba2d85c444bd693778de5093ba91e_0]** 
- The lawsuit claims Nutex misrepresented its progress in addressing **internal control deficiencies** and misclassified stock-based compensation, thereby distorting its financial position.  **[1479681_d56ba2d85c444bd693778de5093ba91e_0]** 
- Following a short-seller report on **July 22, 2025**, Nutex shares dropped over **10%**, and after announcing a delay in its Form 10-Q on **August 14, 2025**, shares plunged **16.39%**.  **[1479681_d56ba2d85c444bd693778de5093ba91e_0]** 
- On **August 21**, Nutex disclosed that its Audit Committee determined certain prior financial statements required **restatement** due to incorrectly classified hospital development obligations.  **[1479681_d56ba2d85c444bd693778de5093ba91e_1]**

Nutex Health Faces Investor Lawsuit Over Alleged Billing Scheme and Financial Restatement

- Nutex Health Inc. is under legal scrutiny due to a class-action lawsuit alleging a **deceptive billing strategy** involving collaboration with third-party firm HaloMD to submit ineligible insurance claims, which artificially boosted financial results.  **[1479681_20251017SF00473:0]** 
- The lawsuit's **Class Period** is **August 8, 2024, to August 14, 2025**, with a **Lead Plaintiff Deadline** of **October 21, 2025**.  **[1479681_20251017SF00473:0]** 
- Allegations gained traction after a **short-seller report** on July 22, 2025, which led to a **drop of over 10%** in Nutex shares, and a subsequent delay in filing its Form 10-Q on August 14, 2025, caused shares to plunge **16.39%**.  **[1479681_20251017SF00473:0]** 
- On August 21, 2025, Nutex disclosed that its Audit Committee determined certain prior financial statements required **restatement** due to incorrect classification of obligations tied to hospital development.  **[1479681_20251017SF00473:0]**

Nutex Health Faces Class-Action Lawsuit Over Alleged Deceptive Billing and Financial Misstatements

- Faruqi & Faruqi, LLP is investigating potential claims against Nutex Health Inc. (NUTX) and reminds investors of the **October 21, 2025 deadline** to seek the role of lead plaintiff in a federal securities class action.  **[1479681_9ad51a9c52f046aba031c6194d63c991_0]** 
- The lawsuit covers investors who purchased or acquired securities in Nutex between **August 8, 2024, and August 15, 2025**.  **[1479681_9ad51a9c52f046aba031c6194d63c991_0]** 
- The complaint alleges that Nutex made false and/or misleading statements, including that revenues from HaloMD were unsustainable due to a fraudulent scheme, and that the company overstated its ability to remediate material weaknesses in internal controls over financial reporting.  **[1479681_9ad51a9c52f046aba031c6194d63c991_0]** 
- Nutex's stock price fell **$11.18 per share (10.05%)** on July 22, 2025, after a Blue Orca Capital short report, and further declined **$18.22 per share (16.39%)** on August 15, 2025, after the company delayed filing its Q2 2025 Form 10-Q due to non-cash accounting adjustments related to stock-based compensation.  **[1479681_9ad51a9c52f046aba031c6194d63c991_0]** **[1479681_9ad51a9c52f046aba031c6194d63c991_1]**

Nutex Health Faces Securities Class Action Lawsuit

- Nutex Health (NUTX) is facing a class-action lawsuit alleging a **deceptive billing strategy** with third-party firm HaloMD to artificially inflate financial results through ineligible insurance claims and exploitation of the arbitration process.  **[1479681_d83a4fc2e74245bda26b17e1a0342bfe_0]** 
- The allegations gained traction after a **July 22, 2025**, short-seller report by Blue Orca Capital, which accused HaloMD of a fraudulent scheme and caused Nutex shares to drop over **10%**.  **[1479681_d83a4fc2e74245bda26b17e1a0342bfe_0]** 
- On **August 14, 2025**, Nutex announced a delay in submitting its Form 10-Q, leading to a **16.39%** share plunge to **$92.91** the following day.  **[1479681_d83a4fc2e74245bda26b17e1a0342bfe_1]** 
- On **August 21, 2025**, Nutex disclosed that its Audit Committee determined certain prior financial statements required **restatement** due to incorrect classification of hospital development obligations.  **[1479681_d83a4fc2e74245bda26b17e1a0342bfe_1]** 
- The lawsuit also asserts that Nutex misrepresented its progress in addressing internal control deficiencies, specifically regarding the misclassification of stock-based compensation.  **[1479681_d83a4fc2e74245bda26b17e1a0342bfe_0]**

Nutex Health Faces Investor Lawsuit and Financial Restatement

- Nutex Health Inc. (NUTX) is facing a class-action lawsuit alleging a **deceptive billing strategy** in collaboration with third-party firm HaloMD, involving ineligible insurance claims and exploitation of the arbitration process to artificially boost financial results.  **[1479681_20251014SF96959:0]**  The Class Period for the lawsuit is **Aug. 8, 2024 – Aug. 14, 2025**, with a Lead Plaintiff Deadline of **Oct. 21, 2025**.  **[1479681_20251014SF96959:0]** 
- The allegations gained traction after a Blue Orca Capital report on **July 22, 2025**, which led to a **10% drop** in Nutex shares, followed by a **16.39% plunge** on **August 15, 2025**, after the company announced a delay in its Form 10-Q submission.  **[1479681_20251014SF96959:0]** 
- On **August 21, 2025**, Nutex disclosed that its Audit Committee determined certain prior financial statements required **restatement** due to misclassified obligations related to hospital development.  **[1479681_20251014SF96959:0]**  The lawsuit also asserts misrepresentation of progress in addressing internal control deficiencies, specifically misclassifying stock-based compensation.  **[1479681_20251014SF96959:0]**

- **Nutex Health Inc. (NASDAQ: NUTX)** is facing a class-action lawsuit alleging a **deceptive billing strategy** with third-party firm HaloMD, which involved submitting ineligible insurance claims to artificially boost financial results.  **[1479681_9b8705f390bb4e88bda534da63f84a31_0]** 
- Following a short-seller report on **July 22, 2025**, Nutex shares dropped over **10%**, and further plunged **16.39%** to **$92.91** on **August 15, 2025**, after the company announced a delay in its Form 10-Q submission.  **[1479681_9b8705f390bb4e88bda534da63f84a31_0]** 
- On **August 21, 2025**, Nutex disclosed that its Audit Committee determined certain prior financial statements required **restatement** due to incorrectly classified obligations tied to hospital development.  **[1479681_9b8705f390bb4e88bda534da63f84a31_1]**